These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Investment advisory firm Ithaka Group released the “Ithaka US Growth Strategy” third-quarter 2024 investor letter. A copy of ...

David Padilla, 77, a Westbury resident, has been living with type 2 diabetes for over 40 years and continues to live life to ...

However, there remain good reasons to invest in the company. Let's first review what DexCom does. The company is a leader in ...

Dexcom in August launched its over-the-counter device Stelo in the U.S. for adults aged 18 and older who do not use insulin, making it the first continuous glucose monitor available for over-the ...

DexCom, Inc. (NASDAQ:DXCM) is a medical device company that develops and commercializes continuous glucose monitoring (CGM) ...

DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

DexCom's stock fell sharply after mixed Q2 earnings and lowering full-year guidance, signaling a revaluation phase with lower ...

Dexcom shares fell on Thursday after the company released third-quarter results that showed slow revenue growth ...

A new device from Abbott Laboratories, called Lingo, is geared toward people who don’t have diabetes but want to see how food and activity affect their glucose levels.

The U.S. spends $413 billion dollars each year on diabetes-related care, meaning that diabetic patients now account for one of every four healthcare dollars spent in the country. The first step in ...